Friday, February 25, 2011
PolyMedix Inc., of Radnor, Pa., completed a Phase I exposure-escalation study with its synthetic defensin-mimetic antibiotic, PMX-30063. Results showed that PMX-30063 may be safely administered at a high dose for more than five days. The data supported dosing levels that are being studied in a current Phase II efficacy study in Staph infections. The results also showed similar pharmacokinetic profiles of PMX-30063 in male and female subjects.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.